Projects / Programmes source: ARIS

Chlamydia pneumoniae in koronarna bolezen (Slovene)

Research activity

Code Science Field Subfield
3.01.00  Medical sciences  Microbiology and immunology   

Code Science Field
B510  Biomedical sciences  Infections 
Chlamdyia pneumoniae, serological studies, PCR, acute myocardial infarction, angina pectoris, coronary heart disease, atherosclerosis
Evaluation (rules)
source: COBISS
Researchers (6)
no. Code Name and surname Research area Role Period No. of publicationsNo. of publications
1.  08312  PhD Bojana Beovič  Microbiology and immunology  Researcher  2000 - 2002 
2.  06311  MSc Janez Kirbiš  Cardiovascular system  Researcher  2000 - 2002 
3.  04573  PhD Mirta Koželj  Cardiovascular system  Researcher  2000 - 2002 
4.  08592  PhD Igor Kranjec  Cardiovascular system  Researcher  2000 - 2002 
5.  11330  PhD Tatjana Lejko-Zupanc  Microbiology and immunology  Head  2000 - 2002 
6.  16183  PhD Mateja Logar  Microbiology and immunology  Researcher  2000 - 2002 
Organisations (1)
no. Code Research organisation City Registration number No. of publicationsNo. of publications
1.  0312  University Medical Centre Ljubljana  Ljubljana  5057272000  125 
We aim to study seroprevalence of antibodies to Chlamydia pneumoniae and their persistence in patients younger than 45 years with acute coronary event (acute myocardial infarction, new angina pectoris and newly diagnosed coronary heart disease (CHD) on coronarography) and presence of Chlamydia pneumoniae in the wall of ascendent aorta in patients with new unstable angina pectoris. 1. Seroprevalence of infection with Chl. pneumoniae and the role of persistent infection in recurrence of coronary event: Only patients, younger than 45 years having a newly diagnosed CHD will be included. Healthy controls without known CHD, matched by sex, age or smoking status will serve as controls. At least 30 patients and two controls for each patient will be included. At the initial coronary event the presence of antibodies to Chl. pneumoniae (IgA, IgM, IgG) will be determined. Additional serology will be performed after three weeks and twice yearly during regular folow-up for three years. Other known risk factor for CHD, as well as epidemiological data and data on possible new chlamydial infection will be recorded. End point of observation will be a recurrence of coronary event. The two groups will be stratified according to other known risk factors and statistically compared as to the persistence or presence of chlamydial antibodies. 2. Presence of Chl. pneumoniae in ascendent aorta in patients with unstable angina pectoris: 50 patients undergoing coronary by-pass graft for unstable angina will be included. Patients with acquired disease of the aortic valve without CHD will serve as controls. Serological tests will be done at the time of opration and during regular follow-ups twice yearly. Direct immunoflourescence and PCR will serve as a method of proving the presence of Chl. pnumoniae in the aortic wall. End point of observation will be recurrence of angina, acute myocardial infarction or restenosis. Multivariate analysis will be used for statistical analysis and to exclude confounding by other known risk factor for CHD.
Views history